{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:56:25Z","timestamp":1793840185818,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T00:00:00Z","timestamp":1489968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T00:00:00Z","timestamp":1489968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss State Secretariat for Education, Research and Education"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10637-017-0454-z","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T03:38:47Z","timestamp":1489981127000},"page":"766-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-7529","authenticated-orcid":false,"given":"A.","family":"Stathis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Homicsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Griguolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Allegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. V.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Xyrafas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Enoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Swiss Group for Clinical Cancer Research (SAKK)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,20]]},"reference":[{"key":"454_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nrc1229","volume":"3","author":"M Pasca di Magliano","year":"2003","unstructured":"Pasca di Magliano M, Hebrok M (2003) Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903\u2013911","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"454_CR2","doi-asserted-by":"publisher","first-page":"5924","DOI":"10.1158\/1078-0432.CCR-06-1736","volume":"12","author":"M Evangelista","year":"2006","unstructured":"Evangelista M, Tian H, de Sauvage FJ (2006) The hedgehog signaling pathway in cancer. Clin Cancer Res 12(20):5924\u20135928","journal-title":"Clin Cancer Res"},{"key":"454_CR3","first-page":"181","volume":"1805","author":"S Teglund","year":"2010","unstructured":"Teglund S, Toftgard R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805:181\u2013208","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"454_CR4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1634\/theoncologist.2011-0450","volume":"17","author":"S Sahebjam","year":"2012","unstructured":"Sahebjam S, Siu LL, Razak AA (2012) The utility of hedgehog signaling pathway inhibition for cancer. Oncologist 17(8):1090\u20131099","journal-title":"Oncologist"},{"issue":"12","key":"454_CR5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/nrd2086","volume":"5","author":"LL Rubin","year":"2006","unstructured":"Rubin LL, de Sauvage FJ (2006) Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov 5(12):1026\u20131033","journal-title":"Nat Rev Drug Discov"},{"key":"454_CR6","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171\u20132179","journal-title":"N Engl J Med"},{"issue":"6","key":"454_CR7","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol Jun 16(6):716\u2013728","journal-title":"Lancet Oncol Jun"},{"issue":"25","key":"454_CR8","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","volume":"23","author":"MC Green","year":"2005","unstructured":"Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983\u20135992","journal-title":"J Clin Oncol"},{"issue":"10","key":"454_CR9","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol 26(10):1642\u20131649","journal-title":"J Clin Oncol"},{"issue":"9","key":"454_CR10","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","volume":"20","author":"M Markman","year":"2002","unstructured":"Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L et al (2002) Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer. J Clin Oncol 20(9):2365\u20132369","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"454_CR11","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S1040-8428(02)00103-8","volume":"44","author":"H Thomas","year":"2002","unstructured":"Thomas H, Rosenberg P (2002) Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Crit Rev Oncol Hematol 44(Suppl):S43\u2013S51","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"454_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2008.01.007","volume":"109","author":"M Linch","year":"2008","unstructured":"Linch M, Stavridi F, Hook J, Barbachano Y, Gore M, Kaye SB (2008) Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecol Oncol 109(1):27\u201332","journal-title":"Gynecol Oncol"},{"issue":"32","key":"454_CR13","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","volume":"33","author":"AM Poveda","year":"2015","unstructured":"Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergotte I et al (2015) Bevacuzumab combined with weekly paclitaxel, pegylated liposomal doxorubicin or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomised phase III AURELIA trial. J Clin Oncol 33(32):3836\u20133838","journal-title":"J Clin Oncol"},{"issue":"38","key":"454_CR14","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.1038\/sj.onc.1210356","volume":"26","author":"J Sims-Mourtada","year":"2007","unstructured":"Sims-Mourtada J, Izzo JG, Ajani J, Chao KS (2007) Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26(38):5674\u20135679","journal-title":"Oncogene"},{"issue":"7","key":"454_CR15","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1158\/1535-7163.MCT-11-1058","volume":"11","author":"AD Steg","year":"2012","unstructured":"Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM et al (2012) Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther 11(7):1587\u20131597","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"454_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"7","key":"454_CR17","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1158\/1078-0432.CCR-13-1710","volume":"20","author":"J Rodon","year":"2014","unstructured":"Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J et al (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation trial of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20(7):1900\u20131909","journal-title":"Clin Cancer Res"},{"issue":"10","key":"454_CR18","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1158\/1078-0432.CCR-12-3654","volume":"19","author":"A Jimeno","year":"2013","unstructured":"Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL et al (2013) Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 19(10):2766\u20132774","journal-title":"Clin Cancer Res"},{"issue":"5","key":"454_CR19","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/1078-0432.CCR-14-1116","volume":"21","author":"AJ Wagner","year":"2015","unstructured":"Wagner AJ, Messesmith WA, Shaik MN, Li S, Zheng X, McLachlan KR et al (2015) Phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21(5):1044\u20131051","journal-title":"Clin Cancer Res"},{"issue":"5","key":"454_CR20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-14-1234","volume":"21","author":"J Goldman","year":"2015","unstructured":"Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E et al (2015) Phase I dose-escalation trial of the oral investigational hedgehog pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res 21(5):1002\u20131009","journal-title":"Clin Cancer Res"},{"issue":"15","key":"454_CR21","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/cncr.30062","volume":"122","author":"CP Belani","year":"2016","unstructured":"Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N (2016) Vismodegib or cixutumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: a trial of the ECOG-ACRIN cancer research group (E1508). Cancer 122(15):2371\u20132378","journal-title":"Cancer"},{"issue":"36","key":"454_CR22","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","volume":"33","author":"DV Catenacci","year":"2015","unstructured":"Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR et al (2015) Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol 33(36):4284\u20134292","journal-title":"J Clin Oncol"},{"issue":"1","key":"454_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/1078-0432.CCR-12-1800","volume":"19","author":"J Berlin","year":"2013","unstructured":"Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC et al (2013) A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 19(1):258\u2013267","journal-title":"Clin Cancer Res"},{"issue":"3","key":"454_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MPA.0000000000000458","volume":"45","author":"AH Ko","year":"2016","unstructured":"Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S et al (2016) A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas 45(3):370\u2013375","journal-title":"Pancreas"},{"key":"454_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2016.04.014","volume":"99","author":"MC Pietanza","year":"2016","unstructured":"Pietanza MC, Litvak AM, Varghese AM, Krug LM, Fleisher M, Teitcher JB et al (2016) A phase I trial of the hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. Lung Cancer 99:23\u201330","journal-title":"Lung Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0454-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:09:20Z","timestamp":1678511360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0454-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,20]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0454-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,20]]},"assertion":[{"value":"14 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author A. Stathis declares that has no conflict of interest. Author D. Hess declares that is shareholder of Novartis. Author R. von Moos declares that is advisory board participant of Novartis and BMS. Author K. Homicsko declares that has no conflict of interest. Author G. Griguolo declares that has no conflict of interest. Author M. Joerger declares that has no conflict of interest. Author M. Mark declares that has no conflict of interest. Author C.J. Ackermann declares that has no conflict of interest. Author S. Allegrini declares that has no conflict of interest. Author C.V. Catapano declares that has no conflict of interest. Author A. Xyrafas declares that has no conflict of interest. Author M. Enoiu declares that has no conflict of interest. Author S. Berardi declares that has no conflict of interest. Author P. Gargiulo declares that has no conflict of interest. Author C. Sessa declares that has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted as an investigator initiated trial within the Swiss Group for Clinical Cancer Research (SAKK). Novartis provided sonidegib free of charge and financial support. This study was also supported by the Swiss State Secretariat for Education, Research and Innovation (SERI).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}